Épisodes

  • Dexcom's 15-Day G7 Is Here: What's Changing, What's Next, and What You Need to Know

    Dexcom's 15-Day G7 Is Here: What's Changing, What's Next, and What You Need to Know
    Dec 16 2025

    It's been a big month for announcements from Dexcom! What does that mean for you?

    From the commercial launch of the 15 day sensor and a smart basal feature to the announced phase out of the G6 and more, I'm talking with Jessica Castle, vice president of Global Medical Affairs at Dexcom. We're covering all of this news and she's answering your questions.

    More about the Dexcom 15 day here

    More about Dexcom G6 phase out here

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Voir plus Voir moins
    31 min
  • Inside Capitol Hill's Fight for Diabetes Care: What These Advocates Need You to Know

    Inside Capitol Hill's Fight for Diabetes Care: What These Advocates Need You to Know
    Dec 9 2025
    We're looking at some major policy issues happening in Washington, and what you can really do to effect change. George Huntley is the CEO of DPAC, the Diabetes Patient Advocacy Coalition. We've got a lot to cover: Medicare changes like competitive bidding that could dramatically limit access to CGMs and insulin pumps for seniors, the changing landscape around GLP 1 meds, and we talk about patient advocacy wins. I know some of you are cynical, but it can work. If you've ever thought your voice doesn't matter, this conversation may change your mind. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. Keywords Diabetes, D-PAC, Medicare, GLP-1 medications, patient advocacy, healthcare access, insulin pumps, CGMs, diabetes technology, legislative reform AI info below: Summary In this conversation, George Huntley, CEO of the Diabetes Patient Advocacy Coalition (D-PAC), discusses the critical role of advocacy in improving diabetes care and access to technology. He highlights the challenges faced by patients, particularly regarding Medicare coverage for insulin pumps and continuous glucose monitors (CGMs), and the implications of recent legislative changes. The discussion also covers the potential of GLP-1 medications in diabetes management and the importance of patient stories in advocacy efforts. Takeaways D-PAC focuses on affordable and equitable access to diabetes care. Advocacy is crucial for influencing healthcare policies. Competitive bidding for diabetes technology could limit access for seniors. Patient stories are essential in legislative advocacy. GLP-1 medications show promise in reshaping diabetes treatment. Economic factors play a significant role in healthcare access. The aging population of type 1 diabetes patients requires urgent attention. Collaboration among advocacy groups is vital for success. Healthcare costs are driven more by major medical expenses than by drug prices. Continued advocacy is necessary to protect patient access to care. Chapters 00:00 Introduction to Diabetes Advocacy 03:01 The Role of D-PAC in Diabetes Care 05:53 Challenges in Medicare Coverage for Diabetes Technology 09:11 The Impact of Competitive Bidding on Seniors 11:55 Advocacy Efforts and Legislative Challenges 14:57 The Future of GLP-1 Medications 17:56 Economic Implications of Diabetes Management 21:01 The Importance of Patient Advocacy 23:59 Healthcare Costs and Insurance Dynamics 26:56 The Need for Continued Advocacy 29:54 Conclusion and Call to Action
    Voir plus Voir moins
    36 min
  • In the News... Libre Freestyle recall, Dexcom 15 day launch, Omnipod & Tandem updates, Medicare price adjustments and more!

    In the News... Libre Freestyle recall, Dexcom 15 day launch, Omnipod & Tandem updates, Medicare price adjustments and more!
    Dec 5 2025
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration. Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free. The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available. "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said. https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries. Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology. New with Dexcom G7 15 Day: Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users ...
    Voir plus Voir moins
    8 min
  • Preventing Type 1 Diabetes? Dr. Michael Haller on ATG Research (Plus, Afrezza for Kids)

    Preventing Type 1 Diabetes? Dr. Michael Haller on ATG Research (Plus, Afrezza for Kids)
    Dec 2 2025

    We've got a research update on two of the topics you've told me you want to hear more about. First, research into Preventing type 1 – with a therapy that hasn't been in the headlines.. and second, inhaled insulin for kids.

    We're talking to Dr. Michael Haller, a peds endo who is at the forefront of these studies. We'll be talking about something called ATG – which looks really good in very low dose trials – and about the latest studies around inhaled insulin for kids – which is in front of the FDA right now.

    ATG studies and info here

    Afrezza for kids info here

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Voir plus Voir moins
    42 min
  • Rethinking Type 1 Screening with Adam Schefter & Dr. Shara Bialo

    Rethinking Type 1 Screening with Adam Schefter & Dr. Shara Bialo
    Nov 25 2025

    With lots of family time coming up this week for many of us, it's a great time to talk about screening for type 1. While this might seem to be a real downer of a Thanksgiving conversation, screening is now considered standard of care for people with a family history of T1D.

    My guests want to get the word out about that – and they've both walked the walk. Adam Schefter is ESPN Senior NFL Insider – his wife lives with type 1.. and Dr. Shara Bialo is a pediatric endo who lives with type 1.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    More information about screening here

    Our previous episodes about TZIELD here

    Listen to our Thanksgiving themed episodes here

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Voir plus Voir moins
    33 min
  • Diabetes Sports Project: Competing at the highest levels with type 1 diabetes

    Diabetes Sports Project: Competing at the highest levels with type 1 diabetes
    Nov 18 2025

    The Diabetes Sprots project says it's an organization built to inspire. What can we all learn about elite athletes with type 1 – the people running marathons and doing Iron Man competitions. And with the right support and education, how far can those athletes go? We're talking about the Olympics and more with DSP founder Casey Boren and volunteer Lauren Adams, both of whom live with type 1 (and both of whom had done a ten mile run before we started taping).

    Learn more about Diabetes Sports Project here

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Voir plus Voir moins
    43 min
  • In the News... It's World Diabetes Day! Top stories and headlines for Nov 14, 2025

    In the News... It's World Diabetes Day! Top stories and headlines for Nov 14, 2025
    Nov 14 2025
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups. Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in ...
    Voir plus Voir moins
    13 min
  • Inside Tandem's Latest: catching up with VP of Product Management Marisa Fienup

    Inside Tandem's Latest: catching up with VP of Product Management Marisa Fienup
    Nov 11 2025

    We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Information on RocketAP and other closed loop research

    Tandem earnings call info here

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Voir plus Voir moins
    38 min